A Molecular On/Off Switch for CRISPRTechnology NetworksThis image shows how the CRISPR surveillance complex is disabled by two copies of anti-CRISPR protein AcrF1 (red) and one AcrF2 (light green). These anti-CRISPRs block access to the CRISPR RNA (gre… Continue reading
Bacterium-based immunotherapyNature.comAnaerobic bacteria can accumulate and proliferate within hypoxic and necrotic regions of solid tumours, stimulating inflammation and triggering an antitumour immune response. Zheng et al. have engineered an attenu… Continue reading
Reuters |
Novartis says US regulator grants speedy review of CAR–T cell therapy
Reuters The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers. The therapy involves a patient’s own T–cells being altered in … Novartis Makes Plans For Its Cancer-Killing T CellsForbes Novartis Says CAR–T Cell Therapy BLA Granted FDA Priority ReviewNasdaq Does the drama of the CAR–T race actually matter?STAT MedCity News –Endpoints News –Healio all 10 news articles » |
Forbes |
Novartis says US regulator grants speedy review of CAR–T cell therapy
Reuters The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers. The therapy involves a patient’s own T–cells being altered in … Novartis Makes Plans For Its Cancer-Killing T CellsForbes Novartis gets speedy review for CAR–T cell therapyPharmaTimes Novartis Says CAR–T Cell Therapy BLA Granted FDA Priority ReviewNasdaq pharmaphorum –STAT –MedCity News all 15 news articles » |
|
Stem cells A case of metabolic identity in the intestinal crypt
Nature.com How does metabolism contribute to epithelial renewal in the intestinal crypt? According to a new study published in Nature, LGR5+ crypt base columnar cells (CBCs) and Paneth cells — key constituents of the intestinal stem cell niche — have different … |
Forbes |
Novartis Makes Plans For Its Cancer-Killing T Cells
Forbes There’s a race on to be the first company to launch what’s a CAR-T — a technology that genetically alters cancer patients’ white blood cells to kill tumor cells. (It stands for chimeric antigen receptor T–cell, which means “white blood cells with … Novartis Says CAR–T Cell Therapy BLA Granted FDA Priority ReviewNasdaq First come, first served: Novartis finalizes CAR–T application, claims priority reviewMedCity News Does the drama of the CAR–T race actually matter?STAT Endpoints News –Healio all 7 news articles » |